An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease

Current Opinion in Rheumatology

Volumn 27, Issue 1, 2015, Pages 24-31

  Cheon, Jae Hee ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Antitumor necrosis factor agent; Diagnostic criteria; Disease activity index; Immunomodulator; Intestinal beh et's disease

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; THALIDOMIDE; ANTIINFLAMMATORY AGENT;

ALGORITHM; BEHCET DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; ENDOSCOPIC THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SURGERY; LONG TERM CARE; MEDICAL ASSESSMENT; OUTCOME ASSESSMENT; PATIENT HISTORY OF SURGERY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT RESPONSE; BEHCET SYNDROME; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEALTH; INTESTINAL DISEASES; MORBIDITY; PROCEDURES; SURVIVAL RATE; TRENDS;

ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; INTESTINAL DISEASES; MORBIDITY; SURVIVAL RATE;

EID: 84918593777     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000125     Document Type: Review

References (59)

1. Bechgaard P. Et tilfaelds af recidiverende aphtos stomatitis ledsaget af conjunctivitis og ulcerationer paa genitalia og hud. Ugeskr Laeger 1940; 102:1019-1023.
2. Tsukada S, Yamazaki T, Iyo S, et al. Neuro-Behçet's syndrome: report of two cases and review of the literature. Saishin Igaku 1964; 19:1533- 1541.
3. Mizuki N, Ohno S. Immunogenetic studies of Behcet's disease. Revue du rhumatisme (English ed) 1995; 63:520-527.
4. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's Disease. Semin Arthritis Rheum 1998; 27:197-217.
5. Shimizu T, Ehrlich GE, Inaba G, et al. Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979; 8:223-260.
6. Yazici Y, Yurdakul S, Yazici H. Behcet's syndrome. Curr Rheumatol Rep 2010; 12:429-435.
7. Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet's disease. J Clin Gastroenterol 2000; 30:144-154.
8. Yi SW, Cheon JH, Kim JH, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behçet's disease: A single center experience in Korea. J Korean Med Sci 2009; 24:52-56.
9. Kim SU, Cheon JH, Lim JS, et al. Massive gastrointestinal bleeding due to aneurysmal rupture of ileo-colic artery in a patient with Behcet's disease. Korean J Gastroenterol 2007; 49:400-404.
10. Criteria for diagnosis of Behcet's, disease. International Study Group for Behcet's Disease. Lancet 1990; 335:1078-1080.
11. Mizushima Y, Inaba G, Mimura Y, et al. Diagnostic criteria for Behçet's disease in and guideline for treating Behçet's disease. Saishin Igaku 1988; 43:391- 393.
12. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol 2007; 42:737-745.
13. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009; 104:2492-2499.
14. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011; 17:605-613.
15. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: Indication of anti-TNF alpha monoclonal antibodies. J Gastroenterol 2014; 49:156-162.
16. Jung YS, Cheon JH, Park SJ, et al. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013; 58:496-503.
17. Yoo HM, Han KH, Kim PS, et al. Clinical features of intestinal Behoet's disease and therapeutic effects of sulfasalazine. Korean J Gastroenterol 1997; 29:465-472.
18. Houman MH, Hamzaoui K. Promising new therapies for Behcet's disease. Eur J Intern Med 2006; 17:163-169.
19. Sonta T, Araki Y, Koubokawa M, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease. J Clin Gastroenterol 2000; 30:195-199.
20. Matsukawa M, Yamasaki T, Kouda T, et al. Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behcet's disease, and simple ulcers. J Gastroenterol 2001; 36:255-258.
21. Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012; 46:e38- e45.
22. Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Engl J Med 1999; 341:1284-1291.
23. Toda K, Shiratori Y, Yasuda M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behcet's disease. J Gastroenterol 2002; 37:844-848.
24. Park JJ, Cheon JH, Moon CM, et al. W1321 long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget's disease. Gastroenterology 2010; 138:S698-S699.
25. Takada Y, Saigenji K. Is intestinal Behcet's disease in fact an enterocolitis or an ulcer disease, and is steroid treatment useful or harmful? J Gastroenterol 2003; 38:1015-1016.
26. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000; 43:692- 700.
27. Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis 2012; 18:750-757.
28. Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflamm Bowel Dis 2010; 16:188-189.
29. Wong RC, Ellis CN, Diaz LA. Behcet's disease. Int J Dermatol 1984; 23:25- 32.
30. Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behcet disease. Inflamm Bowel Dis 2008; 14:396-400.
31. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:443-450.
32. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17:135-139.
33. Lee HJ, Cheon JH, Lee KJ, et al. Clinical experience of thalidomide in the treatment of Korean patients with intestinal Behcet's disease: pilot experience in a single center. Intest Res 2010; 8:63-69.
34. Gul A. Behcet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001; 19:S6-S12.
35. Hassard PV, Binder SW, Nelson V, et al. Antitumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: A case report. Gastroenterology 2001; 120:995-999.
36. Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49:725-728.
37. Kram MT, May LD, Goodman S, et al. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46:118-121.
38. Mussack T, Landauer N, Ladurner R, et al. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 2003; 98:703-704.
39. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet's disease: report of a case. Dis Colon Rectum 2007; 50:672-676.
40. Ju JH, Kwok SK, Seo SH, et al. Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab: rapid healing of Behcet's ulcer with infliximab. Clin Rheumatol 2007; 26:1383-1385.
41. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008; 14:1259-1264.
42. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti- TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011; 21:184-191.
43. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: A Korean multicenter retrospective study. Inflamm Bowel Dis 2013; 19:1833-1838.
44. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003; 17:131-137.
45. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behcet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009; 15:1769-1771.
46. Hisamatsu T, Naganuma M, Matsuoka K, et al. Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014; 7:205-212.
47. Ma D, Zhang CJ, Wang RP, et al. Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014.
48. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations. Rheumatology (Oxford) 2007; 46:736-741.
49. Rossi G, Moretta A, Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 2004; 103:748-750.
50. Yamato K. Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behcet disease. Int J Hematol 2003; 77:82- 85.
51. Lee KS, Kim SJ, Lee BC, et al. Surgical treatment of intestinal Behcet's disease. Yonsei Med J 1997; 38:455-460.
52. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000; 95:2848-2851.
53. Jung YS, Hong SP, Kim TI, et al. Early versus late surgery in patients with intestinal Behcet disease. Dis Colon Rectum 2012; 55:65-71.
54. Lee HW, Kim WH, Cheon JH. The Medical treatments of intestinal Behçet's disease: An update. Intest Res 2013; 11.
55. Jung YS, Yoon JY, Hong SP, et al. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. Inflamm Bowel Dis 2012; 18:1064-1071.
56. Kim DK, Yang SK, Byeon JS, et al. Clinical manifestations and course of intestinal Behcet's disease: An analysis in relation to disease subtypes. Intest Res 2005; 3:48-54.
57. Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet's disease. Yonsei Med J 2013; 54:1084-1090.
58. Kim JS, Lim SH, Choi IJ, et al. Prediction of the clinical course of Behcet's colitis according to macroscopic classification by colonoscopy. Endoscopy 2000; 32:635-640.
59. Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings. Dig Dis Sci 2010; 55:2904-2911.